Patient-Derived Xenograft (PDX) Models
Crown Bioscience's PDX collection consists of over 3,000+ well-characterized models that supports translational preclinical oncology research for over thirty human cancer types. Including rare indications and highly-specific molecular targets. Click a cancer type below to learn more about our models.
Our TMA Model Portfolio
HuPrime® patient-derived xenograft arrays across indications like colorectal, lung, liver, melanoma, pancreatic, sarcoma—perfect for biomarker validation and preclinical insights.
Cell line-derived xenograft arrays offering homogeneous tumor microarrays for precision oncology assays.
Immunocompetent, murine syngeneic models designed for immuno-oncology research.
Murine tumor homograft arrays that provide reproducible, high-throughput platforms.
Ethically sourced, clinically annotated FFPE arrays for direct translational and clinical biomarker validation.
Utilize TMAs derived from our extensive HuPrime® PDX models. Access tissues from colorectal, lung, pancreatic, and gastric cancer models for highly relevant preclinical studies.
Access ethically sourced and clinically annotated human TMAs, essential for clinical biomarker validation, patient stratification, and human-relevant translational research.
Screen I/O targets using TMAs built from our Syngeneic and MuPrime™ murine tumor homograft models, providing essential immunocompetent tumor tissue.
Get TMAs derived from Cell Line-Derived Xenograft models. These arrays provide mixed tumor types for broad, efficient initial screening and biomarker exploration.
